AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06286072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education and message
Description: COPD general education content and fatigue-specific coping strategies. Messages sent to phones
Study NCT04775108 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epygon™ Transcatheter Mitral Valve System
Description: The EPYGON VALVE is an innovative mitral valve, intended for valve replacement of a native mitral valve through a minimally invasive implant procedure by means of a dedicated implant device.~The EPYGON VALVE is a bio prosthesis, composed by a functional assembly of bovine pericardium on a NiTinol stent.
Study NCT05057546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Description: GnRH antagonist will be given once for premenopausal women (12-week intervention) and twice for postmenopausal women (24-week intervention)
Study NCT06570668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDD-2101
Description: All subjects will receive 4 sachets of CDD-2101 and/or placebo at a time based on the computer-generated randomization. An unblinded pharmacist will mix the assigned dose of CDD-2101 and/or placebo with 400 mL of water at 70-80°C, cool it to a comfortable temperature and keep it at room temperature for not longer than 1 h. A blinded study nurse or investigator will dispense the suspension to the assigned subject. The subject will drink it under supervision within 15 minutes.
Study NCT05854199 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth solution
Description: Telehealth nutrition education platform
Study NCT05621551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: The patients is required to receive dapagliflozin(10mg, q.d.) at least for 3 days until 24 hours before the surgery. Then dapagliflozin will be discontinued and recovered as soon as the patient is able to take oral diet postoperatively. Dapagliflozin wil be ceased five days after surgery.
Study NCT04676217 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative positioning advice
Description: The postoperative positioning advice until 3 am the same day.
Study NCT04676217 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postoperative positioning advice
Description: The postoperative positioning advice until 3 am the same day.
Study NCT06051409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olverembatinib
Description: Orally, once every other day (QOD).
Study NCT06051409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: Orally, once daily (QD).
Study NCT05360849 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Practice Facilitation
Description: Participating clinics will work with a Practice Facilitator to modify clinic processes to improve delivery of PrEP to women who inject drugs
Study NCT05400798 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adipose Derived Regenerative Cells
Description: single injection of adipose-derived regenerative cells (ADRCs) into the partial-thickness rotator cuff tear
Study NCT05400798 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: a single corticosteroid injection into the associated subacromial space
Study NCT06350773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil 20 mg then 40 mg if tolerated
Description: Patients will receive tadalafil for 12 week follow up period, in addition to the conventional anti failure therapy.
Study NCT05663268 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab-dyyb biosimilar
Description: Remsima for subcutaneous injection is a biosimilar monoclonal antibody of infliximab-dyyb that inhibits the activity of tumour necrosis factor (TNF)-alpha.
Study NCT06065423 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manuel Lymphatic Drainage(MLD), Exercises
Description: MLD:It is a unique massage technique that uses specific hand movements to provide a gentle pumping effect on the skin.~Massage movements follow the direction of lymph flow and produce rapid results. The aim of this method is to achieve maximum skin tightening effect with minimum pressure.~Exercise, on the other hand, increases physical performance, improves body composition, and provides an increase in quality of life by providing acute and chronic reductions in fatigue. Both aerobic exercises and strengthening exercises have been found effective on physical performance. It shows that a mixed program consisting of components such as aerobics, strengthening, coordination and stretching can positively affect flexibility, pain and energy expenditure in breast cancer patients.
Study NCT06065423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manuel Lymphatic Drainage(MLD), Exercises
Description: MLD:It is a unique massage technique that uses specific hand movements to provide a gentle pumping effect on the skin.~Massage movements follow the direction of lymph flow and produce rapid results. The aim of this method is to achieve maximum skin tightening effect with minimum pressure.~Exercise, on the other hand, increases physical performance, improves body composition, and provides an increase in quality of life by providing acute and chronic reductions in fatigue. Both aerobic exercises and strengthening exercises have been found effective on physical performance. It shows that a mixed program consisting of components such as aerobics, strengthening, coordination and stretching can positively affect flexibility, pain and energy expenditure in breast cancer patients.
Study NCT05577871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: infusion of dexmedetomidine during the off pump coronary artery bypass grafting surgery
Study NCT05577871 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: infusion of normal saline during the off pump coronary artery bypass grafting surgery
Study NCT05478863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo
Description: Placebo will be orally self-administered by study participants.
Study NCT05478863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral THC
Description: THC will be orally self-administered by study participants.
Study NCT05478863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral CBD
Description: CBD will be orally self-administered by study participants.
Study NCT05478863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Caffeine
Description: Caffeine will be orally self-administered by study participants.
Study NCT05237271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Materials on the Cardiovascular Disease in Type 2 Diabetes (CVD-T2D)
Description: Educational Materials will detail the diagnostic tests in question. This CVD-T2D will provide a numerical risk score for the likelihood of patients with type 2 diabetes to have a cardiovascular event in the next 4 years.
Study NCT06408246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine
Description: Guanfacine immediate release is an established and safe FDA-approved treatment that acts directly by stimulating α2A adrenoceptors.
Study NCT06408246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Sertraline is a well-tolerated FDA-approved antidepressant that is among the most widely prescribed medications for depression.
Study NCT06570668 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CDD-2101
Description: All subjects will receive 4 sachets of CDD-2101 and/or placebo at a time based on the computer-generated randomization. An unblinded pharmacist will mix the assigned dose of CDD-2101 and/or placebo with 400 mL of water at 70-80°C, cool it to a comfortable temperature and keep it at room temperature for not longer than 1 h. A blinded study nurse or investigator will dispense the suspension to the assigned subject. The subject will drink it under supervision within 15 minutes.
Study NCT06569654 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Saebo splint
Description: The SaeboFlex orthosis was fitted individually for each participant in the intervention group. The orthosis was adjusted to ensure proper alignment and comfort.~Participants were instructed on how to don and doff the orthosis correctly and safely.~The orthosis positions the wrist and fingers in extension in preparation for grasp and release activities, enabling participants to perform functional tasks despite limited voluntary movement.~Task-Oriented Repetitive Training:~The intervention consisted of 45-minute sessions, conducted twice a week, over a period of 12 weeks.~Each session focused on repetitive, task-oriented exercises designed to improve motor function and enhance neuroplasticity.~Training Activities:~* Moving the Ball~* Bringing the Ball to the Mouth~* Reaching Towards a Target~* Manipulating the Ball Around a Target~* Placing the Ball into Tubes~* Throwing the Ball~* Catching a Rolling Ball
Study NCT05237271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Materials on the CVD-T2D and Bundled Metabolic Panel
Description: Educational Materials will detail the diagnostic tests in question.his CVD-T2D will provide a numerical risk score for the likelihood of patients with type 2 diabetes to have a cardiovascular event in the next 4 years. The bundled metabolic scores will provide insight into the patient's current metabolic conditions.
Study NCT05411900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BoNT-A
Description: A vial of 500 units of BoNT-A will be reconstituted with 2 mL of saline solution (0.9%) and 1 mL of lidocaine solution (2%) to obtain a final concentration of BoNT-A of 166.6 units/mL.~Injections will be repeated at sites 1-1.5 cm apart (0.1 ml, 16.6 units per site), up to 20 sites (333 units).~To reduce pain caused by the injection, lidocaine and prilocaine cream will be applied to the skin area 60 min before the procedure. Additionally, ice could be applied for a few seconds (4-8) before each injection of 16.6 units of BoNT-A.~Injections will be repeated at week 0 and week 12.~The active treatment and placebo solutions will be transparent and indistinguishable to maintain treatment blindness.
Study NCT05411900 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will consist of equal volume of saline solution (0.9%). Injections will be repeated at sites 1-1.5 cm apart (0.1 ml, 16.6 units per site), up to 20 sites (333 units).~To reduce pain caused by the injection, lidocaine and prilocaine cream will be applied to the skin area 60 min before the procedure. Additionally, ice could be applied for a few seconds (4-8) before each injection.~Injections will be repeated at week 0 and week 12.~The active treatment and placebo solutions will be transparent and indistinguishable to maintain treatment blindness.
Study NCT06549309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JMKX003801
Description: For Ascending Single Dose of JMKX003801，Five（5）cohorts of 40 participants (each cohort contains 6 active and 2 placebo) are planned for evaluation.~For Ascending Multiple Dose of JMKX003801，Three（3）cohort of 30 participants (each cohort contains 8 active and 2 placebo) are planned for evaluation.
Study NCT06549309 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For Ascending Single Dose of JMKX003801，Five（5）cohorts of 40 participants (each cohort contains 6 active and 2 placebo) are planned for evaluation.~For Ascending Multiple Dose of JMKX003801，Three（3）cohorts of 30 participants (each cohort contains 8 active and 2 placebo) are planned for evaluation.
Study NCT06292507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MYOFASCIAL STRETCH
Description: Group A 10 participants will receive Myofascial Stretching
Study NCT06292507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CONTRACT-RELAX TECHNIQUE
Description: group B 10 participants will receive Control-Relax Stretching Technique.
Study NCT05733377 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Arrow Test
Description: It consists of taking the widest measurement between the rope of a plumb bob on her upper and lower back.
Study NCT05733377 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Angle measurement by imaging device
Description: First, three anatomical landmarks are located, and a sticker is placed on each of them: the 12th thoracic vertebra at its intersection with the midline descending from the axilla, the greater trochanter, and the anterior superior iliac spine. After this, the woman will be asked to stand in a normal position facing forward with her hands crossed over her shoulders, and a picture will be taken and pixelated with anything that could identify her. The angle formed by the three stickers will be measured with this image and the software.
Study NCT05529602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physical therapy
Description: core stability exercises~A total of 3 sessions per week were given for 15-20 minutes
Study NCT05529602 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: relaxation exercise
Description: the experimental group was given Post-isometric relaxation exercise along with core stability~A total of 3 sessions per week were given for 15-20 minutes
Study NCT05663554 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WW Intervention
Description: The core of the WW food program is the SmartPoints® system. Briefly, the SmartPoints® system assigns each food and beverage a SmartPoints® value per volume based on four components: calories, sugar, saturated fat, and protein. Certain foods have a SmartPoints® value of zero (ZeroPoint foods). These foods (e.g., lean sources of protein such as skinless chicken breast and vegetables) form the basis of a healthy eating pattern, are at low risk for overconsumption and do not have to be weighed, measured or tracked. Participants were assigned a personalized SmartPoints® Budget, based on reported food and lifestyle preferences, and designed to create an energy deficit, using the Mifflin St-Jeor formula, which uses age, sex, height, and weight to estimate resting energy expenditure.
Study NCT05663554 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The Usual Care group will continue to receive routine medical care by their provider, in addition to receiving one 50-minute virtual on-line session of nutrition counseling with a registered dietitian, with additional materials at the time of their 6- and 12-month follow-up assessments.
Study NCT04883047 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: holistic birth support strategies
Description: Holistic Birth Support Strategies are composed of birth-supporting practices that were created by Horn and D'Angelo (2017) within the scope of the Algorithm for Coping with Birth Pain and recommended for coping with labor pain. Holistic Birth Support Strategies; It includes four parameters: physical comfort, emotional comfort, informative support and advocacy.
Study NCT04706325 — intervention group
Intervention type: OTHER
Intervention: ACUTE KIDNEY INJURY
Description: KDIGO LEVELS
Study NCT05867121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7496353
Description: RO7496353 will be administered as per the schedules specified in the respective arms.
Study NCT05867121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as per the schedules specified in the respective arms.
Study NCT05867121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be administered as per the schedules specified in the respective arms
Study NCT06498180 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Periodontal initial treatment under local anesthesia
Description: Removal of plaque retention factors, supragingival scaling and subgingival scraping under local anesthesia with articaine (combined with manual and ultrasound methods), and polishing
Study NCT06498180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoid Therapy
Description: Local blockade therapy with Betamethasone Sodium Phosphate Injection (containing 1.4mg Betamethasone equivalent), local use of 1% Triamcinolone Acetate Ointment, and rinsing with 1% Sodium Bicarbonate (avoiding systemic use during visits)
Study NCT06498180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoid Therapy
Description: Local blockade therapy with Betamethasone Sodium Phosphate Injection (containing 1.4mg Betamethasone equivalent), local use of 1% Triamcinolone Acetate Ointment, and rinsing with 1% Sodium Bicarbonate (avoiding systemic use during visits)
Study NCT04962646 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carbon dioxide flooding
Description: Once the thoracic cavity is opened a flow of carbon dioxide of 5L/min will be initiated into the surgical wound and proceed until there is no connection between the cardiac or aortic cavity and surrounding air.
Study NCT06421207 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ellacor® Micro-Coring procedure
Description: ellacor® Micro-Coring Technology is FDA approved for use by medical professionals for the treatment of moderate and severe wrinkles in the mid and lower face in adults aged 22 years or older with Fitzpatrick skin types I-IV.
Study NCT05806723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 Mg Oral Tablet
Description: daily drug intake during six months
Study NCT05093348 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Click2Print artificial eye
Description: Digitally designed and manufactured ocular prosthesis
Study NCT05093348 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hand-made artificial eye
Description: Hand-made artificial eye
Study NCT05074043 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: antiviral, surgical
Description: surgical debridment
Study NCT06356090 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Parenting for Anxious Childhood Emotions (SPACE)
Description: SPACE is a parent-based treatment (parent-stand-alone treatment) for parents of youth with anxiety symptoms or OCD. The manualized treatment protocol contains 12 sessions, in which parents are taught to reduce family accommodation (FA) and to increase supportive responses to their child.
Study NCT04579029 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphaticovenous anastomosis surgery combined with near infrared spectroscopy imaging
Description: Lymphoedema is well recognized as a chronic debilitating disease resulting from an abnormal collection of protein-rich fluid within the subcutaneous tissues of the body. Given the need to identify more effective treatments, more recent advances in super microsurgical techniques have seen the introduction of new procedures, perhaps the most successful of which have involved re-routing the lymphatic fluid by using microsurgery to divert small lymphatic channels into venules in the sub-dermal plane (LVA surgery). This procedure is performed under regional or general anaesthetic as a day-case operation, leaving only a few very short scars in the skin of the arm or leg.
Study NCT05867121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 will be administered as per the schedules specified in the respective arms.
Study NCT05867121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered as per the schedules specified in the respective arms.
Study NCT06333821 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Nimotuzumab 400mg
Study NCT06333821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 40mg/m\^2
Study NCT06333821 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiotherapy (EBRT)
Description: External Beam Radiotherapy (EBRT)
Study NCT06333821 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Brachytherapy
Study NCT05867121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered as per the schedules specified in the respective arms.
Study NCT05867121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel will be administered as per the schedules specified in the respective arms.
Study NCT05867121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered as per the schedules specified in the respective arms.
Study NCT06333821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo for Nimotuzumab
Description: placebo for Nimotuzumab 400mg
Study NCT06533254 — intervention group
Intervention type: OTHER
Intervention: Predicting choice of dialysis
Description: Language data collected using survey 1, will be analyzed using Scaled Insights Behavioral AI solution to identify personality attributes and values. The resulting individual scores will be plotted on a graph and be used to identify specific personality clusters of patients.~Participants will respond to a survey that utilizes open and closed ended questions, asking broad questions about kidney failure and associated behaviors (e.g. diet, attitudes towards treatment). The open-ended questions will gather a natural language sample of 100-300 words whilst closed questions will capture data using Likert scale and multiple-choice responses.~The open-ended questions will gather a natural language sample of 100-300 words for analysis using Scaled Insights Behavioral AI approach. This language sample will be analyzed using Scaled Insights Behavioral AI system to identify personality attributes and values. Patients will also be asked their likelihood of selecting PD over HD.